Purchase Order 75F40119P10307

The Department of Health and Human Services Food and Drug Administration awarded a $56,042.50 firm fixed price purchase order to Firalis Molecular Precision SA for MIRNA whole transcriptome assay services in human plasma samples. Firalis, doing business as Firalis and a subsidiary of Firalis, will perform the requested microRNA whole transcriptome assays in human plasma samples to support FDA programs from July 2024 through November 2024. No major subcontractors or set aside designations were...

The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $16,514 purchase order to Arraystar Inc. to provide exosome miRNA profiling and sequencing services. The firm fixed price contract has a period of performance from September 19, 2023 through April 25, 2024 and will be performed in Silver Spring, Maryland. Arraystar will deliver the requested exosome profiling and sequencing services to support HHS FDA programs. No subcontractors or set aside designations...

The Department of Health and Human Services Food and Drug Administration awarded a $21,480 firm fixed price purchase order to Arraystar Inc. to provide transfer RNA sequencing services. The contract has a period of performance from August 1, 2023 through July 31, 2024 and will be performed in Potomac, Maryland. No additional context was provided regarding the FDA's programs or use of the contracted sequencing services. The award was made directly to Arraystar Inc. as the prime contractor, with...

The U.S. Food and Drug Administration (FDA) awarded a $42,455 firm-fixed-price purchase order to Fluigent, Inc., a foreign-owned for-profit organization, for the procurement of microfluidic equipment for organ-on-a-chip studies. This contract, awarded on July 13, 2024, has a completion date of July 14, 2025 and was not set aside for any specific business category. Fluigent, Inc. is a specialized provider of microfluidic solutions, including automated perfusion systems, pressure generators, and...

The Department of Health and Human Services Food and Drug Administration awarded a $39,010.14 firm fixed price delivery order to Illumina, Inc. for Illumina reagent chemistry kits. The place of performance is Jefferson, Arkansas. The contract period of performance runs from June 20, 2023 through September 30, 2023. No set aside designation or subcontractors were identified. The FDA likely utilizes these reagent kits to support laboratory analysis and testing functions that help advance the...

The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $20,940.38 delivery order contract to Biomerieux, Inc. for supplies. The prime contractor Biomerieux, Inc. will perform the work at its Calverton, Maryland facility. The firm fixed price contract runs from May 18, 2022 through July 28, 2026. No additional details were provided regarding the specific supplies requested under the original solicitation. The HHS FDA regulates food and drugs to ensure...

The U.S. Food and Drug Administration (FDA) awarded a $99,413.00 firm-fixed-price purchase order contract to Olink Proteomics Inc., a foreign-owned, for-profit biotechnology company, to conduct cardiotoxicity biomarker analysis on plasma samples from cancer patients. The contract has an ultimate completion date of September 29, 2025. This contract was awarded under a competitive solicitation that was set aside for small businesses under NAICS code 541380 - Testing Laboratories and Services....

The Department of Health and Human Services Food and Drug Administration awarded a $25,184.74 firm fixed price delivery order to Illumina, Inc. for Illumina reagent chemistry kits. The place of performance is Jefferson, Arkansas. The period of performance is from June 27, 2023 through September 30, 2023. The award utilizes no set aside designations. Illumina will provide reagent kits to support the FDA's laboratory testing programs through this delivery order issued against an unidentified...

This is a Cost No Fee definitive contract awarded by the Food and Drug Administration (FDA) to the Arkansas Research Alliance, a non-profit organization, for "Scientific and Methodological Advancements in Liquid Biopsies to Further the Development of Lung Cancer-Based Precision Medicine." The contract has a ceiling value of $754,003.90 and a performance period ending March 31, 2019. This contract was not set aside for any particular socioeconomic program. The contract supports the...

<p>This is a federal contract award from the Food and Drug Administration (FDA) to Girihlet Inc., a minority-owned, woman-owned small business, for sequencing services related to circular RNA. The contract has a ceiling value of $145,000.00 and is a firm fixed-price purchase order. The contract was awarded on September 16, 2015, with an ultimate completion date of October 9, 2016. The contract is set aside for small businesses.</p>